Clinical trial
Phase III Study of AJM300 in Patients With Active Ulcerative Colitis
NCT03531892 is registered in ClinicalTrials.gov with EA Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Study of AJM300 in Patients With Active Ulcerative Colitis
- Lead sponsor
- EA Pharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 6, 2018
- Completion date
- March 28, 2023
- Enrollment
- 198 (actual)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.